)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Hyloris Pharmaceuticals
Hyloris Pharmaceuticals (HYL) investor relations material
Hyloris Pharmaceuticals H2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H2 2025 earnings summary26 Mar, 2026
Executive summary
Royalty income grew 15% year-over-year to €5.6 million, led by MaxigesicⓇ IV and Sotalol IV, despite currency headwinds and Podofilox Gel stock-out issues.
Total operating income declined 12% to €8.8 million due to lower non-recurring milestone revenue and adverse FX effects.
Portfolio expanded to over 30 assets, with six new product additions and eight new out-licensing agreements in 2025.
Net loss remained stable at €6.3 million, reflecting disciplined cost management amid increased R&D investment.
Cash position at year-end was €13.8 million, with no financial debt.
Financial highlights
Royalty income: €5.6 million (+15% YoY); recurring revenues (royalties + product sales): €5.9 million (+20% YoY).
Milestone income: €1.4 million, down 62% YoY due to a large one-off milestone in 2024; excluding this, decline was 14%.
Total revenues: €7.2 million (–15% YoY); operating income: €8.8 million (–12% YoY).
Operating expenses decreased 9% to €15.6 million; R&D expenses rose to €11.3 million (+10% YoY).
Net loss: €6.3 million (unchanged YoY); equity: €26.5 million (–18% YoY).
Cash and cash equivalents: €13.8 million (–42% YoY).
Outlook and guidance
Continued advancement of the development portfolio and strategic growth opportunities supported by strong cash position.
U.S. commercial promotion for MaxigesicⓇ IV expected to intensify from late Q2 2026.
Multiple regulatory submissions and clinical trial completions anticipated in 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Hyloris Pharmaceuticals
- Royalties up 30% to €2.9m, net loss €3.5m, FDA approval, and qualified audit opinion.HYL
H1 202525 Sep 2025 - Rapidly growing portfolio and revenue, targeting unmet needs with innovative, lower-risk medicines.HYLInvestor Presentation13 Jun 2025
- Revenue growth and narrowed loss reflect Maxigesic IV launch, but funding needs remain.HYLH1 202413 Jun 2025
- Rapid portfolio expansion and strong revenue growth position Hyloris as a leader in value-added medicines.HYLInvestor Presentation6 Jun 2025
- Strong revenue growth and new product launches drive Hyloris' expansion in value-added medicines.HYLInvestor Presentation6 Jun 2025
- Revenue up 138%, net loss at post-IPO low, and pipeline targets 30 assets by 2025.HYLH2 20246 Jun 2025
Next Hyloris Pharmaceuticals earnings date
H1 202624 Sep, 2026
Hyloris Pharmaceuticals
Next Hyloris Pharmaceuticals earnings date
H1 202624 Sep, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage